# Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

> **NCT01888952** · EARLY_PHASE1 · COMPLETED · sponsor: **Anand B. Karnad** · enrollment: 10 (actual)

## Conditions studied

- Advanced B-cell Lymphoid Malignancies

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT01888952
- **Lead sponsor:** Anand B. Karnad
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888952, "Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01888952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*